Bruker (BRKR) Resumen de Acciones
Bruker Corporation, junto con sus filiales, desarrolla, fabrica y distribuye instrumentos científicos y soluciones analíticas y de diagnóstico. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 3/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 3/6 |
| Dividendos | 0/6 |
BRKR Community Fair Values
Create NarrativeSee what 29 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Bruker Corporation
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$56.32 |
| Máximo en las últimas 52 semanas | US$65.30 |
| Mínimo de 52 semanas | US$28.53 |
| Beta | 1.28 |
| Cambio en 1 mes | -6.23% |
| Variación en 3 meses | 25.91% |
| Cambio de 1 año | 82.98% |
| Variación en 3 años | -17.91% |
| Variación en 5 años | -32.77% |
| Variación desde la OPV | 144.21% |
Noticias y actualizaciones recientes
Actualización de narrativa • Aug 07
BRKR: Premium Multiple Will Face Earnings Risk After Recent Guidance Miss
The updated analyst price target for Bruker moves from an implied fair value of about $35.00 to approximately $42.30 as analysts balance slightly higher assumed profit margins and P/E expectations, more cautious revenue growth forecasts, and an unchanged mix of Neutral, Hold, Buy, Overweight and Peer Perform ratings across recent research. Analyst Commentary Recent Street research on Bruker shows a mix of enthusiasm and caution, with several firms adjusting price targets and ratings as they reassess valuation, growth assumptions, and execution risks ahead of earnings updates.Seeking Alpha • Aug 05
Weak Growth In Its Primary Market Continues To Weigh Heavily On Bruker Shares
Summary Bruker faces ongoing headwinds from weak academic/government funding that has compressed growth despite strong semiconductor and energy research markets. Q2 delivered strong order growth and margin improvement, but revenue missed expectations and near-term guidance is soft, raising execution risk for FY targets. BRKR's high exposure to academic/government end markets remains a structural challenge, but growth in biopharma, diagnostics, and semiconductor segments offers long-term upside. Valuation appears modestly attractive with potential 30%+ upside, yet tepid organic growth and guidance uncertainty temper immediate buy conviction. Read the full article on Seeking Alpha
Actualización de narrativa • Jul 24
BRKR: Infection Detection Expansion Will Meet Rich Tools Sector Expectations
Bruker’s updated analyst price target of $59.75, up from $56, reflects a series of target increases into the $60 to $70 range as analysts recalibrate their models for life science and diagnostic tools stocks and incorporate what they view as reasonable earnings expectations along with improving sentiment toward the group. Analyst Commentary Recent research updates on Bruker show a wide range of price targets clustered between US$60 and US$70, with most analysts adjusting their models for the life science and diagnostic tools sector ahead of upcoming earnings reports.Recent updates
Actualización de narrativa • Aug 07
BRKR: Premium Multiple Will Face Earnings Risk After Recent Guidance Miss
The updated analyst price target for Bruker moves from an implied fair value of about $35.00 to approximately $42.30 as analysts balance slightly higher assumed profit margins and P/E expectations, more cautious revenue growth forecasts, and an unchanged mix of Neutral, Hold, Buy, Overweight and Peer Perform ratings across recent research. Analyst Commentary Recent Street research on Bruker shows a mix of enthusiasm and caution, with several firms adjusting price targets and ratings as they reassess valuation, growth assumptions, and execution risks ahead of earnings updates.Seeking Alpha • Aug 05
Weak Growth In Its Primary Market Continues To Weigh Heavily On Bruker Shares
Summary Bruker faces ongoing headwinds from weak academic/government funding that has compressed growth despite strong semiconductor and energy research markets. Q2 delivered strong order growth and margin improvement, but revenue missed expectations and near-term guidance is soft, raising execution risk for FY targets. BRKR's high exposure to academic/government end markets remains a structural challenge, but growth in biopharma, diagnostics, and semiconductor segments offers long-term upside. Valuation appears modestly attractive with potential 30%+ upside, yet tepid organic growth and guidance uncertainty temper immediate buy conviction. Read the full article on Seeking AlphaActualización de narrativa • Jul 24
BRKR: Infection Detection Expansion Will Meet Rich Tools Sector Expectations
Bruker’s updated analyst price target of $59.75, up from $56, reflects a series of target increases into the $60 to $70 range as analysts recalibrate their models for life science and diagnostic tools stocks and incorporate what they view as reasonable earnings expectations along with improving sentiment toward the group. Analyst Commentary Recent research updates on Bruker show a wide range of price targets clustered between US$60 and US$70, with most analysts adjusting their models for the life science and diagnostic tools sector ahead of upcoming earnings reports.Actualización de narrativa • Jul 10
BRKR: Diagnostics Portfolio Momentum Will Counter Valuation And Execution Uncertainty
The analyst fair value estimate for Bruker has been raised from $53.25 to $56.00 after analysts responded to a series of higher Street price targets and updated models across diagnostics and life sciences tools coverage. Analyst Commentary Recent Street research on Bruker shows a mix of optimism and caution, with several firms updating price targets and ratings as they refresh models across diagnostics and life sciences tools coverage.Actualización de narrativa • Jun 26
BRKR: Rich Multiple And Execution Risks Will Pressure Earnings Power Into 2026
Bruker’s analyst fair value estimate has been revised from $36.80 to $35.00 as analysts weigh a richer valuation, even as several recent price target increases in the $60 to $65 range cite updated models and improving sentiment toward life science and diagnostic tools stocks. Analyst Commentary Recent Street commentary on Bruker shows a clear divide between optimistic targets and more cautious views that question how much upside is left at current prices.Actualización de narrativa • Jun 11
BRKR: Semiconductor And Diagnostics Momentum Will Balance Helium And Execution Risks
The updated analyst price target for Bruker has moved from an implied fair value of $49.15 to $53.25, reflecting recent target hikes into the $65 range by several firms as analysts incorporate refreshed models, sector sentiment, and valuation concerns into their views. Analyst Commentary Recent research updates show a mix of optimism and caution around Bruker, with price targets clustering around US$65 alongside more neutral stances that focus on valuation and operating risks.Actualización de narrativa • May 28
BRKR: Rising Helium Costs Will Constrain Earnings Power Into 2026
Analysts have lifted their average price target on Bruker by about $1.80, citing updated assumptions that include a slightly lower discount rate, modestly higher revenue growth and profit margin expectations, and a lower future P/E multiple. Analyst Commentary Recent Street research on Bruker reflects a mix of optimism on long term prospects and concern about near term risks.Actualización de narrativa • May 14
BRKR: 2026 Earnings Delivery Will Outweigh Helium Cost Headwinds
Bruker's updated analyst price target has shifted to $49.15 from $47.86, as analysts factor in moderate adjustments to discount rates, revenue growth, profit margins and expected future P/E multiples, following a mix of recent target raises and cuts across the Street. Analyst Commentary Recent research on Bruker reflects a split view, with some analysts lifting price targets and others trimming them, as they reassess valuation, execution risk and potential headwinds in key input costs.Actualización de narrativa • Apr 29
BRKR: Helium Cost Pressures And Margin Execution Will Shape 2026 Path
Analysts have trimmed their average price targets on Bruker by several dollars to reflect helium cost headwinds, recent margin pressure and lower valuation multiples, while underlying long term revenue growth and profit margin assumptions remain broadly consistent. Analyst Commentary Bearish analysts have been resetting expectations on Bruker, with several firms cutting price targets by mid single digit to low double digit dollar amounts.Actualización de narrativa • Apr 15
BRKR: Rising Helium Costs Will Pressure Margins And Test 2026 Earnings
Analysts have reduced their Bruker price targets by mid single digit dollar amounts, citing lower margin expectations, helium related cost headwinds and revised sector multiples. These factors, in turn, feed into a higher implied future P/E and modest adjustments to growth and discount rate assumptions.Actualización de narrativa • Apr 01
BRKR: 2026 Earnings Framework And Helium Risk Will Shape Future P/E
Bruker's updated analyst price target edges lower to about $48 per share, as analysts trim fair value and future P/E assumptions while factoring in helium cost risks and recent price target resets across the coverage group. Analyst Commentary Recent Street research on Bruker reflects a mix of optimism around long term growth targets and caution around nearer term execution, margins, and input cost risks.Actualización de narrativa • Mar 18
BRKR: 2026 Earnings Framework And Spatial Biology Expansion Will Support Higher P/E
Analysts have reduced the average Bruker price target to about $48, citing helium cost headwinds, a Q4 margin miss and lower sector valuation multiples, while noting that longer term earnings expectations remain in place. Analyst Commentary Research commentary on Bruker highlights a mix of optimism on long term earnings power and caution around near term execution risks and input costs, particularly helium.Actualización de narrativa • Mar 03
BRKR: Reset Margins And 2026 Outlook Will Support Higher Forward P/E
Analysts have reset their view on Bruker, trimming the target to about $48 from about $54 as they factor in recent Q4 margin pressure, higher assumed discount rates and lower profit margin expectations. This comes even as revenue growth forecasts and future P/E assumptions move higher and Street research shows a mix of price target cuts and raises across firms.Actualización de narrativa • Feb 17
BRKR: Future Earnings Reset Will Test 2026 Margin Ramp Assumptions
Analysts have trimmed their fair value estimate for Bruker to $35 from $38, reflecting lower applied multiples on future earnings targets after recent price target cuts across several firms, even as updated assumptions factor in changes to revenue growth and profit margins. Analyst Commentary Recent Street research around Bruker has turned more mixed, with several bearish analysts cutting price targets after the latest quarterly update, even as some firms maintain positive ratings or modestly higher targets.Artículo de análisis • Feb 15
Analysts Have Been Trimming Their Bruker Corporation (NASDAQ:BRKR) Price Target After Its Latest Report
It's been a sad week for Bruker Corporation ( NASDAQ:BRKR ), who've watched their investment drop 13% to US$36.51 in...Actualización de narrativa • Feb 03
BRKR: Q4 Setup And BEST Agreements Will Support Higher Forward P/E Multiple
Analysts have lifted their price targets on Bruker by amounts such as $5, $13 and to $53, citing updated views on the life science tools sector and Q4 setups. This feeds into our slightly higher fair value estimate and revised assumptions for discount rate, revenue growth, profit margin and future P/E.Actualización de narrativa • Jan 20
BRKR: Constructive Bookings And Rating Upgrade Will Support Higher Forward P E Multiple
Analysts have lifted their Bruker price target to about $54 from about $52, citing slightly higher fair value estimates and modest adjustments to the discount rate, margin assumptions, and future P/E expectations. These changes are supported by a series of recent target hikes and an upgrade to Hold in the life science tools peer group.Actualización de narrativa • Jan 06
BRKR: Constructive Bookings And Rating Upgrade Will Shape Balanced Forward Expectations
Analysts have raised their price target on Bruker by about US$0.57 to around US$52.36, reflecting updated views that factor in steadier bookings and the recent shift from Sell to Hold in Street ratings. Analyst Commentary Recent Street research on Bruker reflects a more balanced stance, with some analysts turning less negative while still highlighting execution risks and guidance concerns.Actualización de narrativa • Dec 17
BRKR: Constructive Bookings And Rating Upgrade Will Support Stronger Forward Expectations
Analysts have modestly raised their price target on Bruker to about $52 from roughly $49, citing constructive bookings trends that help offset the impact of a 2025 guidance cut and support a slightly higher long term growth and valuation outlook. Analyst Commentary Analyst reactions to Bruker reflect a balanced mix of optimism and caution, with modest target price increases and a shift in ratings signaling improving sentiment but also recognition of execution and guidance risks.Actualización de narrativa • Dec 03
BRKR: Constructive Bookings And Rating Upgrades Will Support Stable Forward Expectations
Analysts have modestly increased their price target on Bruker to approximately $49 from about $48, citing constructive bookings despite 2025 guidance cuts and recent upgrades in rating outlook. Analyst Commentary Analyst reactions to Bruker’s updated outlook highlight a more balanced risk and reward profile, with some modest upward revisions to valuation targets despite tempered near term expectations.Artículo de análisis • Nov 26
Bruker Corporation's (NASDAQ:BRKR) Shares Bounce 26% But Its Business Still Trails The Industry
Bruker Corporation ( NASDAQ:BRKR ) shares have continued their recent momentum with a 26% gain in the last month alone...Actualización de narrativa • Nov 19
BRKR: Booking Momentum Will Improve Sentiment Despite Lowered 2025 Outlook
Analysts have modestly increased their price target for Bruker from $40 to $43, citing more constructive bookings and improved financial metrics, even though 2025 guidance has been lowered. Analyst Commentary Recent analyst updates reflect a complex view of Bruker's prospects, with nuanced shifts in expectations tied to the company's latest financial disclosures and forward guidance.Actualización de narrativa • Nov 03
BRKR: Recent Upgrade Will Drive Confidence In Core Market Resilience
Narrative Update: Bruker Analyst Price Target Increased Analysts have raised Bruker's fair value price target by approximately $1.09 to $47.82, citing improved ratings and updated market assessments, even as growth expectations have moderated slightly. Analyst Commentary Bullish Takeaways Bullish analysts note that the recent price target increase reflects greater confidence in Bruker’s ability to deliver stable financial results in the near term.Actualización de narrativa • Aug 06
Renewed Biopharma Funding And Cost Savings Will Revitalize Markets
Bruker's consensus analyst price target has declined notably, primarily due to weaker revenue growth forecasts and a lower forward P/E multiple, resulting in a reduced fair value estimate of $46.73. What's in the News Bruker provided guidance for FY2025, projecting revenues of $3.43-$3.50 billion (2%-4% reported growth), driven mainly by M&A (3.5%) and FX tailwind (2.5%), but expects 2%-4% organic revenue decline; Q2 2025 revenue is projected to be approximately flat year-over-year at $795-$798 million (Key Developments).Rentabilidad de los accionistas
| BRKR | US Life Sciences | Mercado US | |
|---|---|---|---|
| 7D | -12.4% | 3.6% | 2.7% |
| 1Y | 83.0% | 25.6% | 20.9% |
Rentabilidad vs. Industria: BRKR superó a la industria US Life Sciences, que obtuvo un rendimiento del 25.6% el año pasado.
Rentabilidad vs. Mercado: BRKR superó al mercado US, que obtuvo un rendimiento del 20.9% el año pasado.
Volatilidad de los precios
| BRKR volatility | |
|---|---|
| BRKR Average Weekly Movement | 10.3% |
| Life Sciences Industry Average Movement | 8.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: BRKR no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de BRKR (10%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1960 | 11,085 | Frank Laukien | www.bruker.com |
Bruker Corporation, junto con sus filiales, desarrolla, fabrica y distribuye instrumentos científicos y soluciones analíticas y de diagnóstico. Opera a través de cuatro segmentos: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano y Bruker Energy & Supercon Technologies. La empresa ofrece espectroscopia de resonancia magnética, imagen preclínica, biofarmacéutica y aplicada, servicios y soporte del ciclo de vida, solución integrada de datos y automatización; herramientas de ciencias de la vida; productos innovadores de resonancia magnética nuclear (RMN) y resonancia paramagnética electrónica (EPR); soluciones para procesos in vivo y descubrimiento de fármacos; soluciones posventa; soluciones para la automatización y digitalización de laboratorios; soluciones y kits de pruebas de espectrometría de masas, tiras reactivas de ADN y tecnologías PCR basadas en fluorescencia; kits de diagnóstico molecular de genotipos y fluorotípicos; e instrumentos y soluciones de investigación, análisis y análisis de procesos.
Resumen de fundamentos de Bruker Corporation
| Estadísticas fundamentales de BRKR | |
|---|---|
| Capitalización bursátil | US$8.14b |
| Beneficios(TTM) | -US$106.90m |
| Ingresos (TTM) | US$3.50b |
2.5x
Ratio precio-ventas (PS)-80.3x
Ratio precio-beneficio (PE)¿Está BRKR sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de BRKR | |
|---|---|
| Ingresos | US$3.50b |
| Coste de los ingresos | US$1.80b |
| Beneficio bruto | US$1.70b |
| Otros gastos | US$1.80b |
| Beneficios | -US$106.90m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.70 |
| Margen bruto | 48.48% |
| Margen de beneficio neto | -3.05% |
| Ratio deuda/patrimonio | 75.4% |
¿Cómo se ha desempeñado BRKR a largo plazo?
Ver rendimiento histórico y comparativaDividendos
0.4%
Rentabilidad actual por dividendo-28%
Ratio de pagosAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/10 01:54 |
| Precio de las acciones al final del día | 2026/08/10 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Bruker Corporation está cubierta por 32 analistas. 12 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |